Cilengitide: A Prototypic Integrin Inhibitor for the Treatment of Glioblastoma and Other Malignancies

Por Reardon, David A., Cheresh, David
Publicado em 2011

Introduction

Por Reardon, David A., Weller, Michael
Publicado no Neuro Oncol (2015)

Dedication: Andrew T. Parsa

Por Reardon, David A., Weller, Michael
Publicado no Neuro Oncol (2015)

Treatment options and outcomes for glioblastoma in the elderly patient

Por Arvold, Nils D, Reardon, David A
Publicado em 2014

A Review of Micro and Macro Vascular Analyses in the Assessment of Tumor-Associated Vasculature as Visualized by MR

Por Bullitt, Elizabeth, Reardon, David A., Smith, J. Keith
Publicado em 2007

Current available therapies and future directions in the treatment of malignant gliomas

Por Desjardins, Annick, Reardon, David A, Vredenburgh, James J
Publicado em 2009

Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges

Por Reardon, David A., Wen, Patrick Y., Mellinghoff, Ingo K.
Publicado em 2014

Primary central nervous system tumors pathogenesis and therapy /

Por Norden, Andrew D., Reardon, David A., Wen, Patrick Y. C.
Publicado em 2011

Experience with irinotecan for the treatment of malignant glioma

Por Vredenburgh, James J., Desjardins, Annick, Reardon, David A., Friedman, Henry S.
Publicado em 2009

Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme

Por Reardon, David A, Nabors, L Burt, Stupp, Roger, Mikkelsen, Tom
Publicado em 2008

Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy

Por Reardon, David A., Gilbert, Mark R., Wick, Wolfgang, Liau, Linda
Publicado no Neuro Oncol (2015)

Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response

Por Huang, Raymond Y., Neagu, Martha R., Reardon, David A., Wen, Patrick Y.
Publicado no Front Neurol (2015)

Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy

Por Reardon, David A, Wen, Patrick Y, Desjardins, Annick, Batchelor, Tracy T, Vredenburgh, James J
Publicado em 2008

A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas

Por Nghiemphu, Phioanh Leia, Lai, Albert, Green, Richard M., Reardon, David A., Cloughesy, Timothy
Publicado em 2012

Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects

Por Batchelor, Tracy T., Reardon, David A., de Groot, John F., Wick, Wolfgang, Weller, Michael
Publicado no Clin Cancer Res (2014)

Prospects of immune checkpoint modulators in the treatment of glioblastoma

Por Preusser, Matthias, Lim, Michael, Hafler, David A., Reardon, David A., Sampson, John H.
Publicado no Nat Rev Neurol (2015)

Targeted α-Particle Radiotherapy with (211)At-labeled Monoclonal Antibodies

Por Zalutsky, Michael R., Reardon, David A., Pozzi, Oscar R., Vaidyanathan, Ganesan, Bigner, Darell D.
Publicado em 2007

Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials

Por Han, Kelong, Ren, Melanie, Wick, Wolfgang, Abrey, Lauren, Das, Asha, Jin, Jin, Reardon, David A.
Publicado em 2014

Impact of imaging measurements on response assessment in glioblastoma clinical trials

Por Reardon, David A., Ballman, Karla V., Buckner, Jan C., Chang, Susan M., Ellingson, Benjamin M.
Publicado em 2014

Interpretation of meta-analysis evaluating progression-free survival as a surrogate endpoint for overall survival in glioblastoma

Por Han, Kelong, Ren, Melanie, Wick, Wolfgang, Abrey, Lauren, Das, Asha, Jin, Jin, Reardon, David A.
Publicado no Neuro Oncol (2015)